首页> 外文OA文献 >BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI-PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL)

【2h】

BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI-PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL)

机译：具有抗PD-L1抗体的PD-1检查点Avelumab足以进行复发/难治性典型霍奇金淋巴瘤（CHL）的临床活性。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
R. Chen; A.L. Gibb; G.P. Collins; R. Popat; D. El-Sharkawi; C. Burton; D. Lewis; F.M. Miall; A. Forgie; A. Compagnoni; G. Andreola; S. Brar; A. Thall; A. Woolfson; J. Radford;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate [J] . Santoro Armando, Castagna Luca, Magagnoli Massimo, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：用编程的细胞死亡-1（PD-1）检查后的同种异体干细胞移植（Allo-SCT）用于复发/难治性经典霍格金淋巴瘤（R / R CHL）的检查点抑制剂与前所未有的低复发率相关
2. 791?A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL) [J] . Yuqin Song, Keshu Zhou, Chuan Jin, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：791？在复发或难治经典霍奇金淋巴瘤（CHL）患者中，对抗程序化细胞死亡-1（PD-1）抗体Penpulimab的II期研究
3. Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study [J] . Amraee A., Evazi M. R., Shakeri M., Clinical & translational oncology : . 2019,第8期

机译：Nivolumab作为检查点抑制剂药物对复发/难治古典霍奇金淋巴瘤患者存活率的疗效：前瞻性临床研究的荟萃分析
4. Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 [O] . Robert Chen, Phillippe Armand, Michelle A Fanale, 2015

机译：派姆单抗（MK-3475）用于复发/难治性经典霍奇金淋巴瘤（r / r cHL）的II期研究：主题演讲087
5. 791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL) [O] . Yuqin Song, Keshu Zhou, Chuan Jin, 2020

机译：791复发或难治经典霍奇金淋巴瘤（CHL）患者中的抗程序化细胞死亡-1（PD-1）抗体Penpulimab的II期研究

BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI-PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL)

著录项

引文网络

相似文献

相关主题

期刊订阅